IMMUNITYBIO INC
ImmunityBio Inc. (IBRX) is a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases. It pursues a pipeline of biologics, engineered cell approaches and vaccine candidates intended to stimulate or modulate the immune system, using viral-vector and cytokine-based platforms. With a market capitalisation of about $2.40 billion, the stock reflects investor expectations about its clinical programmes and potential commercial opportunities. Key value drivers include trial read-outs, regulatory decisions, partnerships and financing. Like most clinical-stage biotechs, it carries higher volatility and binary outcomes — successful trials can materially increase value, while setbacks can lead to sharp declines. Investors should monitor cash runway, R&D spending and pipeline progress. This summary is educational and not personal financial advice; suitability depends on your circumstances and you should consult a qualified financial adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ImmunityBio's stock with a target price of $10.4, indicating growth potential.
Financial Health
ImmunityBio is performing well with strong profits, high revenue, and solid cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring IBRX
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical read-outs and regulatory milestones can move the share price significantly, though outcomes are binary and uncertain.
Platform Technology
Viral-vector and cytokine-based approaches aim to enhance immune response; technological promise requires clinical validation.
Funding & Partnerships
Collaborations and capital raises affect runway and commercial prospects, but financing can dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
